Iconovo CEO Dr. Orest Lastow took part in an FDA workshop on the evaluation of new methods for characterizing and demonstrating equivalence of OINDP. The workshop was a part of the new GDUFA II initiative and the objective was to discuss how science and technology can be used to reduce the time and effort to register a generic IONDP in the US. It was a fantastic opportunity to discuss this important topic with senior FDA officials and industry representatives.